Delving into the Latest Updates on Tirzepatide with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Tirzepatide (USAN), TZP, ZEHP-bownd

+ [16]

Target

GIPR x GLP-1R

Action

agonists

Mechanism

GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseRespiratory Diseases+ [8]

Active Indication

Obesity Hypoventilation SyndromeSleep Apnea, ObstructiveObesity+ [14]

Inactive Indication

HypoglycemiaKidney Failure, ChronicLiver Injury+ [2]

Originator Organization

Lexaria Bioscience Corp.

Eli Lilly & Co.

Active Organization

Eli Lilly Japan KK

Eli Lilly & Co.

Lilly Asia Shanghai Representative Office

+ [8]

Inactive Organization-

License Organization

Eli Lilly Japan KK

Eli Lilly & Co.

Tanabe Pharma Corp.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (13 May 2022),

Diabetes Mellitus, Type 2

RegulationFast Track (United States), Breakthrough Therapy (China), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 10195070

Source: *****

This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date01 Dec 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07349641

/ Not yet recruitingPhase 2IIT

Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women

This phase II trial studies whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response (absence of cancer cells in tissue samples after treatment) in women with endometrial atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or grade 1 endometrial cancer who are overweight or obese. Endometrial cancer occurrence has continued to rise in the United States. Over half of endometrial cancer cases are thought to be attributable to being overweight and obese, and the risk relationship appears to be weight dependent. AH/EIN is a precancerous condition of the endometrium (the uterus or womb) where the lining of the uterus grows abnormally thick, and the cells become abnormal. Women with this thickening have a higher-than-average risk of developing endometrial cancer if left untreated. The usual approach for patients who have AH/EIN and grade 1 endometrial cancer is the removal of the uterus. While surgical treatment is generally safe and effective, it may not be the best approach for some patients. Tirzepatide injections are a type of glucagon-like peptide 1 (GLP-1) agonist which have been shown to drive weight loss. The LNG-IUD is a small, T-shaped device inserted into the uterus that releases the hormone levonorgestrel. Levonorgestrel is being studied in the prevention of endometrial cancer. Adding tirzepatide injections to LNG-IUD may help overweight or obese women with AH-EIN or grade 1 endometrial cancer lose weight, which may improve pathologic response.

Start Date06 Jul 2026

Sponsor / Collaborator

National Cancer Institute

NCT07265752

/ Not yet recruitingPhase 2IIT

Tirzepatide for the Treatment of Cannabis Use Disorder: A Pilot Double-blind, Placebo-controlled, Crossover Trial

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Start Date01 Jul 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

100 Clinical Results associated with Tirzepatide

Login to view more data

100 Translational Medicine associated with Tirzepatide

Login to view more data

100 Patents (Medical) associated with Tirzepatide

Login to view more data

1,558

Literatures (Medical) associated with Tirzepatide

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation

Article

Author: Yao, Tie-Feng ; Yu, Sheng-Xue ; Sun, Lu ; Yu, Hong-Dan ; Yao, Su-Yan ; Zuo, Zhong-Fu ; Lu, Si-Jing ; Hou, Yang ; Zheng, Han-Song ; Sun, Qing-Lin

01 Apr 2026·American journal of preventive cardiology

Addressing patient concerns about the ‘newness’ and long-term safety of GLP-1 receptor agonists: A clinician’s guide to counseling

Article

Author: Bhattacharya, Romit ; Shah, Priyansh P

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are "new" or unproven. This commentary equips clinicians with practical counseling strategies to reframe the "newness" narrative and address long-term safety concerns. We provide a brief history of GLP-1 from its discovery in the 1980s to nearly two decades of clinical use, underscoring that GLP-1RAs are the product of extensive research rather than experimental novelties. We compare native GLP-1 to newer agents like semaglutide and tirzepatide, highlighting structural modifications that prolong action without fundamentally altering the hormone's mechanism. Known safety data are summarized emphasizing the predominance of mild, transient gastrointestinal side effects and the lack of evidence for feared risks like cancer along with how to discuss these points. A practical counseling checklist and sample patient-centric language are included to facilitate shared decision-making. In sum, clinicians can confidently reassure patients that GLP-1RAs are well-studied, mechanism-based therapies with millions of patient-years of experience supporting their safety and efficacy.

01 Mar 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database

Article

Author: Murray, Mya ; Schifano, Fabrizio ; Chiappini, Stefania ; Corkery, John Martin ; Guirguis, Amira

PURPOSE:

As use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Type 2 diabetes (T2DM) and weight management increases, emerging research identifies various adverse drug reactions. This study aimed to expand this research base, focusing on eye disorders in people with and without T2DM, a novel consideration.

DESIGN:

A retrospective clinical cohort disproportionality analysis of reports made to the Food and Drug Administration Adverse Event Reporting System (FAERS).

METHODS:

FAERS was queried regarding selected GLP-1RAs. Python 3.11 was adopted to develop a program, quantifying reported cases between January 2017 - September 2025 (January 2022-September 2025 for tirzepatide) meeting the criteria for cases with and without T2DM. Main outcome measures Reporting Odds Ratios (RORs) >4.000 and 95% confidence intervals were calculated, with metformin and orlistat as controls.

RESULTS:

Compared to metformin, semaglutide showed increased reporting of optic ischemic neuropathy (ROR: 12.269 [0.915-1.967]), cataract (ROR: 31.879 [2.463-4.461]) and retinopathy (ROR: 5.185 [0.556-2.736]) in T2DM patients, and retinopathy (ROR: 9.424 [1.081-3.406]) and retinal hemorrhage (ROR: 10.253 [0.319-4.336]) in non-T2DM patients. Tirzepatide showed increased reporting of optic ischemic neuropathy (ROR: 4.619 [0.726-2.335]) and macular degeneration (ROR: 15.579 [0.554-4.938]) in T2DM patients and eye swelling (ROR: 6.475 [0.407-3.329]) in non-T2DM patients. Liraglutide showed increased reporting of cataract (ROR: 53.866 [2.945-5.028]), diabetic retinopathy (ROR: 18.162 [1.753-4.045]) and macular degeneration (ROR: 26.261 [1.076-5.460]) in T2DM patients and cataract (ROR: 9.628 [1.387-3.142]) and macular degeneration (ROR: 9.557 [0.110-4.405]) in non-T2DM patients.

CONCLUSIONS:

These results provide a signal of increased reporting of various eye disorders with GLP-1RA use compared to metformin across T2DM and non-T2DM patient cases. Further research is required to support these findings and confirm a biological causation.

1,641

News (Medical) associated with Tirzepatide

10 Feb 2026

·www.prnewswire.com

Nation's Largest Thyroid Cancer Center Publishes White Paper Finding No Convincing Evidence That GLP-1 Medications Cause Common Thyroid Cancers

Comprehensive review aims to clarify growing public concern around Ozempic®, Wegovy®, and Mounjaro® TAMPA, Fla., Feb. 10, 2026 /PRNewswire/ -- With the rapid rise in use of GLP-1 receptor agonist medications such as Ozempic®, Wegovy®, and Mounjaro® for diabetes and weight loss, public concern has grown over a possible link to thyroid cancer. A newly released white paper from the Clayman Thyroid Center offers a comprehensive review of the scientific evidence and concludes that the best available human data do not show these medications cause (or have any effect upon) the most common types of thyroid cancer. The white paper, titled "Do GLP-1 Weight-Loss Shots Like Ozempic and Mounjaro Really Raise Thyroid Cancer Risk? The Latest Facts Explained," examines mechanistic research, clinical trials, large population studies, and real-world clinical experience. Its central message: much of the current fear is driven by misunderstanding rather than strong human evidence. "Thyroid cancer is not a single disease, and that distinction matters," said Gary L. Clayman, MD, FACS, FACE, senior author of the white paper and an extremely high-volume thyroid cancer surgeon. "The FDA boxed warning tied to GLP-1 medications is specific to a rare cancer called medullary thyroid carcinoma. It does not apply to the common thyroid cancers that account for more than 95 percent of cases." The FDA warning originated from rodent studies in which animals developed C-cell tumors when exposed to GLP-1 drugs. However, important biological differences exist between rodents and humans, and large human studies have not demonstrated a similar pattern. According to the Clayman Thyroid Center's review, major international cohort studies and meta-analyses have not found increased thyroid cancer rates among GLP-1 users. Some studies showing possible "associations" may be explained by detection bias. Patients on GLP-1 therapy often have more medical visits, imaging, and specialist care, which can increase the likelihood of discovering pre-existing thyroid nodules or small cancers that might otherwise remain undetected. "When diagnoses rise shortly after starting a medication, that pattern often reflects finding something that was already there," said Rashmi Roy, MD, FACS, co-author of the white paper. "That is very different from a drug actually causing a new cancer." The review emphasizes that for patients with papillary, follicular, or Oncocytic (Hürthle cell) thyroid cancers, current evidence does not support the idea that GLP-1 medications cause these diseases or worsen their course. For these individuals, decisions about GLP-1 therapy should be individualized, considering metabolic benefits and overall health goals. However, the authors stress that caution remains appropriate for a small, specific group. GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia type 2 (MEN2), consistent with existing FDA labeling. The Clayman Thyroid Center treats approximately 2,000 thyroid cancer patients each year and is among the highest-volume thyroid centers in the world. Within this large clinical practice, surgeons have not observed a pattern linking GLP-1 use to medullary thyroid carcinoma. "In a practice that sees more thyroid cancer than almost anywhere globally, we are not seeing a surge of medullary thyroid cancer linked to these medications," Dr. Clayman said. The authors also caution that oversimplified headlines and social media summaries can blur important distinctions between cancer subtypes and exaggerate risk. Such confusion can lead patients to discontinue beneficial medications or experience unnecessary anxiety. "Patients deserve clear, evidence-based guidance," Dr. Roy said. "Our goal is to provide clarity so people can make informed decisions with their physicians." The full white paper is available through the Clayman Thyroid Center's website and is intended as a resource for clinicians, patients, and media navigating this complex topic. About the Clayman Thyroid Center Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center in the United States. The Center boasts the most experienced thyroid surgeons in the US who provide personalized care allowing the greatest opportunity for cancer cure, wellness, and cosmetic, and functional, outcomes via all types of thyroid surgery from minimal incision to scarless thyroid surgery to advanced cancer care. | (813) 940-3130 SOURCE Clayman Thyroid Center 21% more press release views with Request a Demo

10 Feb 2026

·www.fiercebiotech.com

Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill

Kailera Therapeutics and its China partner Hengrui have released top-line results from a phase 2 trial of their obesity pill which indicate that it has a “potentially game-changing clinical profile,” according to Kailera’s Scott Wasserman, M.D.\n In October of last year, Kailera Therapeutics unveiled a whopping $600 million series B financing raised to fund a phase 3 trial of its injected, dual-agonist obesity drug ribupatide.Four months later, the Massachusetts biotech and its China partner Hengrui have released top-line results from a phase 2 trial of their oral version of ribupatide, which indicate that it has a “potentially game-changing clinical profile,” according to Kailera Chief Medical Officer Scott Wasserman, M.D.The study, which included 166 patients in China, demonstrated a mean weight loss of up to 12.1% over 26 weeks. The trial’s efficacy figure assumes that participants adhered to protocol treatment and excludes data collected after premature discontinuation or use of other weight loss therapies from the analysis, the companies explained.Based on this estimand, participants taking a 10-mg daily dose of oral ribupatide achieved a mean weight loss of 6.9%. Those on doses of 25 mg and 50 mg each achieved a mean weight loss of 12.1%. There was no observed plateau in weight reduction, and the figures compare to a 2.3% efficacy figure for those on placebo.While cross-trial comparisons can be challenging, the mean weight loss figure in a study that paved the way for the recent approval of Novo Nordisk’s GLP-1 pill was 16.6%. Meanwhile, in a trial of Eli Lilly’s orforglipron, which the company expects will be approved in the second quarter of this year, the dual-agonist pill provided a 12.4% mean reduction in weight. A key difference between the trials, however, is that these were conducted over 64 and 72 weeks respectively, while Hengrui’s study lasted 26 weeks. As for side effects, ribupatide rates of vomiting were 2.4% at 10 mg, 11.4% at 25 mg and 7.5% at 50 mg, while nausea was reported for 11.9% of patients in the 10-mg arm, 22.7% in the 25-mg group and 20% in the 50-mg arm. In the Novo study, 31% of participants reported vomiting, while Lilly’s trial showed vomiting at a rate between 14% and 32%, depending on the dosing. “The Hengrui phase 2 clinical trial results mark an important milestone in the expansion of our ribupatide franchise,” Wasserman said in the release. “We believe oral ribupatide could help to address the diverse needs of people living with obesity or overweight and meet patients wherever they are in their treatment journey.”Wasserman added that the company would initiate a phase 2 trial of oral ribupatide this year, while Hengrui’s chief of clinical development of its metabolic diseases unit, Zi Ye, said the company plans to advance the treatment this year to a phase 3 study in China. Obesity drug specialist Kailera launched in October 2024 with a $400 million series A funding round. Its top candidate, which has allowed the company to secure much of its funding, is injected ribupatide, or KAI-9531. The treatment is touted by the company as having a long half-life, allowing it to have more consistent exposure during a weekly dosing period.A phase 3 trial of KAI-9531 in China showed in July of last year that it provided a mean weight loss of 19.2% at its highest 6-mg dose after 36 weeks, compared to a 20.9% weight loss figure for Lilly’s injected obesity treatment Zepbound.

Clinical ResultPhase 2Phase 3

10 Feb 2026

·www.fiercebiotech.com

OrsoBio hits target in midstage study for metabolic conditions but stays silent on details

A proof-of-concept study was examining the safety of TLC-2716, which OrsoBio said was “generally well tolerated.” \n OrsoBio’s experimental oral drug lowered fasting triglyceride levels at four weeks of treatment, hitting the primary efficacy goal in a midstage study of metabolic conditions.The California company is evaluating TLC-2716, a liver X receptor (LXR) inverse agonist, among patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction–associated steatotic liver disease (MASLD), the latter of which is a common condition tied to risk factors like obesity, diabetes and high blood pressure.OrsoBio’s phase 2a trial recruited 30 adults who were overweight, had fasting triglycerides equal to or higher than 350 mg/dL and showed evidence of MASLD per imaging tests. The study tested out once-daily TLC-2716 at two different dose levels, examining the drug’s ability to change fasting triglycerides—a measure of lipids in the blood—and treatment-emergent adverse events. At four weeks, the biotech’s oral drug was tied to reductions in fasting triglycerides compared to baseline, while also demonstrating clinically meaningful improvements in remnant cholesterol and hepatic fat, according to OrsoBio. The company did not disclose any data, with more details expected to be shared at an upcoming scientific conference.The proof-of-concept study was also examining the safety of TLC-2716, which the California biotech said was “generally well tolerated,” with zero grade 3 or higher adverse events occurring. OrsoBio is now “exploring financing options to move this compound into the next phase of development, which will be a phase 2b study,” a company spokesperson told Fierce, adding that the biotech is open to a partnership but is currently pursuing a path to move forward independently. “These phase 2a data provide compelling clinical validation of LXR inverse agonism as a differentiated therapeutic strategy for severe metabolic disorders,” OrsoBio\'s chief medical officer and development head, Rob Myers, M.D., said in a Feb. 10 release.“The substantial reductions in triglycerides, remnant cholesterol and other atherogenic lipids—along with improvements in liver fat and a favorable safety profile—support the potential of TLC-2716 to become a meaningful therapeutic option for patients with diseases driven by excessive lipid production, including SHTG, MASH and elevated remnant cholesterol,” Myers said.MASH, or metabolic dysfunction-associated steatohepatitis, is a more severe form of MASLD, which currently affects about 30% of the world’s population.OrsoBio debuted near the end of 2022 with its sights set on several metabolic diseases. Both CMO Myers and CEO Mani Subramanian, M.D., are alums of Gilead Sciences, where they worked on liver diseases. The company even licensed a liver-targeted mitochondrial protonophore called TLC-6740 from Gilead. At the end of 2025, the asset was tied to an additional 4.5% mean weight loss when paired with tirzepatide versus tirzepatide alone in a phase 1b/2a obesity trial. OrsoBio is planning a phase 2b trial for the asset for this year.As for the liver-targeting TLC-2716, OrsoBio snagged the program from Phenex Pharmaceuticals.

Phase 2Clinical Result

100 Deals associated with Tirzepatide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Reduced ejection fraction co-occurrent and due to chronic heart failure	NDA/BLA	European Union	Eli Lilly & Co.	-
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	23 Dec 2025
Metabolic dysfunction-associated steatotic liver disease	Phase 3	China	Eli Lilly & Co.	23 Dec 2025
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obes Pillars)	Phase 3	Obesity	4,726	Tirzepatide	whfjalluce(ezcuyrafjo) = oqloqejbry thkhxcpqdu (foqbquqdbq ) View more	Positive	01 Mar 2026
				Placebo	iuhwttxaft(zfncpkpfga) = xznqctzuwo kyeefjuyvc (sfgrdvraor ) View more
NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	102	Tirzepatide 5 mg	raoequlymi(oitnoqbcot) = tcdkjtpjzn ldeapsmfhf (ygoqxghtet )	Positive	30 Jan 2026
				Tirzepatide 10 mg	raoequlymi(oitnoqbcot) = fiibyumath ldeapsmfhf (ygoqxghtet )
NCT06588296 (TOGETHER-PsA, Company_Website) Manual	Phase 3	Arthritis, Psoriatic \| Overweight \| Obesity	271	Taltz (ixekizumab) + Zepbound (tirzepatide)	zgtfzxrgvg(wllvzzdpma) = ifjxfuslnj aevyjqdibj (gipjrckdmt ) Met View more	Superior	08 Jan 2026
				Taltz (ixekizumab)	zgtfzxrgvg(wllvzzdpma) = qisbvrclpc aevyjqdibj (gipjrckdmt ) Met View more
NCT04255433 (SURPASS-CVOT, Pubmed \| N Engl J Med)	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,174	Tirzepatide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)	bakqscrhqx(vcsdhncliv) = The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. bynltnanxi (pqwhuzypqd ) View more	-	18 Dec 2025
				Dulaglutide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)
NCT05822830 (SURMOUNT-5, CTgov)	Phase 3	Obesity	751	Tirzepatide (15 mg or MTD - Tirzepatide)	mbceueachm(noaqtcvqzs) = xftcnjrfwe kfuasghjxn (xuzuhymwly, 0.59) View more	-	26 Nov 2025
				Semaglutide (2.4 mg or MTD - Semaglutide)	mbceueachm(noaqtcvqzs) = ihlrwwcxrs kfuasghjxn (xuzuhymwly, 0.59) View more
NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	2,788	Tirzepatide	iiwpqriazt(vakwujbdsu) = jwwtnfiaeu ccocgnmitx (vhizhbccso ) View more	Positive	04 Nov 2025
NCT04657003 \| NCT05536804 \| NCT04184622 (SURMOUNT-1, Pubmed \| J Am Soc Nephrol)	Not Applicable	-	3,477	Tirzepatide	dniiqsdtpq(jnylnrpuoq): Difference (%) = −55.2 (95.0% CI, −68.5 - −36.4) View more	Positive	01 Nov 2025
				Placebo
ACR2025	Not Applicable	Overweight \| Obesity	62,722	Tirzepatide	oviarmyhjo(pwjmzethkw): HR = 0.88 (95.0% CI, 0.81 - 0.95) View more	Positive	24 Oct 2025
				Phentermine
NCT05963022 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	206	Tirzepatide (10 mg Tirzepatide)	xuhdfgfyyr(myldywcsgl) = zxcmdzswet lhoplipvkx (yalepdrsyw, 0.131) View more	-	21 Oct 2025
				Tirzepatide (15 mg Tirzepatide)	xuhdfgfyyr(myldywcsgl) = enyrgwmmvr lhoplipvkx (yalepdrsyw, 0.124) View more
NCT06914141 \| NCT06914154 \| NCT06914102 (Pubmed \| JAMA)	Not Applicable	Heart failure with normal ejection fraction	97,790	Semaglutide	cucinkssun(pzbqpathin): HR = 0.58 (95.0% CI, 0.51 - 0.65) View more	Positive	14 Oct 2025
				Tirzepatide

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Tirzepatide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation